Search

Your search keyword '"VENTURINI, Marina"' showing total 581 results
Start Over Author "VENTURINI, Marina"
581 results on '"VENTURINI, Marina"'

2. Short-term pulse pressure variability: a novel prognostic marker and therapeutic target in patients with vascular Ehlers-Danlos syndrome? Preliminary results from a pilot study

Author

Buso, Giacomo, Gatta, Roberto, Corvini, Federica, Laera, Nicola, Agabiti-Rosei, Claudia, Paini, Anna, Bulgari, Giuseppe, Petroboni, Beatrice, Bertacchini, Fabio, Aggiusti, Carlo, Stassaldi, Deborah, Capellini, Sara, Salvetti, Massimo, De Ciuceis, Carolina, Ritelli, Marco, Venturini, Marina, Colombi, Marina, and Muiesan, Maria Lorenza

Published
2025
Full Text
View/download PDF

4. Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

Author

Malagoli, Piergiorgio, Dapavo, Paolo, Amerio, Paolo, Atzori, Laura, Balato, Anna, Bardazzi, Federico, Bianchi, Luca, Cattaneo, Angelo, Chiricozzi, Andrea, Congedo, Maurizio, Fargnoli, Maria Concetta, Giofrè, Claudia, Gisondi, Paolo, Guarneri, Claudio, Lembo, Serena, Loconsole, Francesco, Mazzocchetti, Giampiero, Mercuri, Santo Raffaele, Morrone, Pietro, Offidani, Anna Maria, Palazzo, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Piaserico, Stefano, Potenza, Concetta, Prignano, Francesca, Romanelli, Marco, Savoia, Paola, Stingeni, Luca, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, and Costanzo, Antonio

Published
2024
Full Text
View/download PDF

9. Update on the Management of Pediatric Psoriasis: An Italian Consensus

Author

Peris, Ketty, Fortina, Anna Belloni, Bianchi, Luca, Fabbrocini, Gabriella, Gisondi, Paolo, Balato, Anna, Bardazzi, Federico, Bernardini, Nicoletta, Bonamonte, Domenico, Bongiorno, Maria Rita, Buligan, Cinzia, Cusano, Francesco, Del Giudice, Maria Beatrice De Felici, El Hachem, May, Fargnoli, Maria Concetta, Gualdi, Giulio, Guarneri, Claudio, Hansel, Katharina, Malara, Giovanna, Mazzatenta, Carlo, Micali, Giuseppe, Narcisi, Alessandra, Neri, Iria, Oranges, Teresa, Panzone, Michele, Parodi, Aurora, Restano, Lucia, Simonetti, Oriana, Venturini, Marina, and Di Lernia, Vito

Published
2022
Full Text
View/download PDF

10. Bridging the Diagnostic Gap for Hypermobile Ehlers‐Danlos Syndrome and Hypermobility Spectrum Disorders: Evidence of a Common Extracellular Matrix Fragmentation Pattern in Patient Plasma as a Potential Biomarker.

Author

Ritelli, Marco, Chiarelli, Nicola, Cinquina, Valeria, Bertini, Valeria, Piantoni, Silvia, Caproli, Alessia, Della Pina, Silvia Ebe Lucia, Franceschini, Franco, Zarattini, Guido, Gandy, Woodrow, Venturini, Marina, Zoppi, Nicoletta, and Colombi, Marina

Abstract

Diagnosing hypermobile Ehlers‐Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD), common overlapping multisystemic conditions featuring symptomatic joint hypermobility, is challenging due to lack of established causes and diagnostic tools. Currently, the 2017 diagnostic criteria for hEDS are used, with non‐qualifying cases classified as HSD, although the distinction remains debated. We previously showed extracellular matrix (ECM) disorganization in both hEDS and HSD dermal fibroblasts involving fibronectin (FN), type I collagen (COLLI), and tenascin (TN), with matrix metalloproteinase‐generated fragments in conditioned media. Here, we investigated these fragments in patient plasma using Western blotting across diverse cohorts, including patients with hEDS, HSD, classical EDS (cEDS), vascular EDS (vEDS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and osteoarthritis (OA), and healthy donors, uncovering distinctive patterns. Notably, hEDS/HSD displayed a shared FN and COLLI fragment signature, supporting their classification as a single disorder and prompting reconsideration of the hEDS criteria. Our results hold the promise for the first blood test for diagnosing hEDS/HSD, present insights into the pathomechanisms, and open the door for therapeutic trials focused on restoring ECM homeostasis using an objective marker. Additionally, our findings offer potential biomarkers also for OA, RA, and PsA, advancing diagnostic and therapeutic strategies in these prevalent joint diseases. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

13. Integrative Multi-Omics Approach in Vascular Ehlers–Danlos Syndrome: Further Insights into the Disease Mechanisms by Proteomic Analysis of Patient Dermal Fibroblasts.

Author

Chiarelli, Nicola, Cinquina, Valeria, Zoppi, Nicoletta, Bertini, Valeria, Maddaluno, Marianna, De Leonibus, Chiara, Settembre, Carmine, Venturini, Marina, Colombi, Marina, and Ritelli, Marco

Subjects
PROTEOMICS, MULTIOMICS, EXTRACELLULAR matrix, ORGAN rupture, CONNECTIVE tissues
Abstract

Background: Dominant mutations in COL3A1 are known to cause vascular Ehlers–Danlos syndrome (vEDS) by impairing extracellular matrix (ECM) homeostasis. This disruption leads to the fragility of soft connective tissues and a significantly increased risk of life-threatening arterial and organ ruptures. Currently, treatments for vEDS are primarily symptomatic, largely due to a limited understanding of its underlying pathobiology and molecular mechanisms. Methods: In this study, we conducted a comprehensive analysis of the intracellular proteome of vEDS fibroblasts, integrating these findings with our previous transcriptome results to identify key molecular pathways that drive the disease. Additionally, we explored the therapeutic potential of inhibiting miR-29b-3p as a proof of concept. Results: Our integrative multi-omics analysis revealed complex pathological networks, emphasizing the critical role of miRNAs, particularly miR-29b-3p, in impairing ECM organization, autophagy, and cellular stress responses, all of which contribute to the pathogenesis of vEDS. Notably, the inhibition of miR-29b-3p in vEDS fibroblasts resulted in the upregulation of several differentially expressed target genes involved in these critical processes, as well as increased protein expression of essential ECM components, such as collagen types V and I. These changes suggest potential therapeutic benefits aimed at improving ECM integrity and restoring intracellular homeostasis. Conclusions: Overall, our findings advance our understanding of the complex biological mechanisms driving vEDS and lay a solid foundation for future research focused on developing targeted and effective treatment strategies for this life-threatening disorder. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Line-field confocal optical coherence tomography for the differential diagnosis of porokeratosis from clinical mimickers: a preliminary study.

Author

Tognetti, Linda, Cappilli, Simone, Falcinelli, Francesca, Soglia, Simone, Lacarrubba, Francesco, Maione, Vincenzo, Ricci, Costantino, Suppa, Mariano, Venturini, Marina, Cinotti, Elisa, Stefani, Alessandro Di, Perrot, Jean Luc, and Rubegni, Pietro

Subjects
OPTICAL coherence tomography, TECHNOLOGICAL innovations, IMAGE analysis, DIFFERENTIAL diagnosis, HISTOLOGY
Abstract

Background Porokeratosis variants are relatively rare and can be clinically misdiagnosed with several common papulokeratotic mimickers. Line-field confocal optical coherence tomography (LC-OCT) is a new technology able to explore the skin in vivo up to a depth of 500 µm. Objectives To investigate the role of LC-OCT in the diagnosis of many porokeratosis variants in a preliminary study. Method In total, 130 LC-OCT images were obtained from 98 patients, 45 affected by a porokeratosis variant (69 images) and 53 with a mimicker condition (61 images). Results We found almost perfect interobserver agreement for LC-OCT image interpretation and perfect correspondence with the findings from histological slides. In addition, a series of morphological in vivo and three-dimensional features related to the cornoid lamella were detected by LC-OCT that were not visible from the histology. Conclusions This device can be proposed to assist with rapid bedside noninvasive differentiation of porokeratosis variants from their mimickers, possibly sparing incisional biopsy in patients where the diagnosis is uncertain. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

Author

Gargiulo, Luigi, primary, Ibba, Luciano, additional, Cascio Ingurgio, Ruggero, additional, Malagoli, Piergiorgio, additional, Amoruso, Fabrizio, additional, Balato, Anna, additional, Bardazzi, Federico, additional, Brianti, Pina, additional, Brunasso, Giovanna, additional, Burlando, Martina, additional, Cagni, Anna E., additional, Caproni, Marzia, additional, Carrera, Carlo G., additional, Carugno, Andrea, additional, Caudullo, Francesco, additional, Cuccia, Aldo, additional, Dapavo, Paolo, additional, Di Brizzi, Eugenia V., additional, Dini, Valentina, additional, Gaiani, Francesca M., additional, Gisondi, Paolo, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Licata, Gaetano, additional, Loconsole, Francesco, additional, Marzano, Angelo V., additional, Megna, Matteo, additional, Mercuri, Santo R., additional, Musumeci, Maria L., additional, Orsini, Diego, additional, Ribero, Simone, additional, Ruffo Di Calabria, Valentina, additional, Satolli, Francesca, additional, Strippoli, Davide, additional, Travaglini, Massimo, additional, Trovato, Emanuele, additional, Venturini, Marina, additional, Zichichi, Leonardo, additional, Valenti, Mario, additional, Costanzo, Antonio, additional, and Narcisi, Alessandra, additional

Published
2024
Full Text
View/download PDF

16. FIRST COMPREHENSIVE ECHOCARDIOGRAPHIC ASSESSMENT IN PATIENTS WITH VASCULAR EHLERS-DANLOS SYNDROME WITH OR WITHOUT CELIPROLOL THERAPY AT THE MAXIMUM RECOMMENDED DOSE

Author

Buso, Giacomo, primary, Paini, Anna, additional, Agabiti-rosei, Claudia, additional, Bertacchini, Fabio, additional, Stassaldi, Deborah, additional, Capellini, Sara, additional, Aggiusti, Carlo, additional, Salvetti, Massimo, additional, De Ciuceis, Carolina, additional, Ritelli, Marco, additional, Venturini, Marina, additional, Colombi, Marina, additional, and Muiesan, Maria Lorenza, additional

Published
2024
Full Text
View/download PDF

17. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Author

Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria C., Flori, Maria L., Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Lo Schiavo, Ada, Malagoli, Piergiorgio, Malara, Giovanna, Mercuri, Santo R., Musumeci, Maria L., Naldi, Luigi, Papini, Manuela, Parodi, Aurora, Potenza, Concetta, Prignano, Francesca, Rongioletti, Franco, Stingeni, Luca, Tiberio, Rossana, Venturini, Marina, Bianchi, Luca, Costanzo, Antonio, Cusano, Francesco, Girolomoni, Giampiero, Offidani, Anna M., and Peris, Ketty

Published
2021
Full Text
View/download PDF

19. Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

Author

Campione, E, Artosi, F, Shumak, R, Giunta, A, Argenziano, G, Assorgi, C, Balato, A, Bernardini, N, Brunasso, A, Burlando, M, Caldarola, G, Campanati, A, Carugno, A, Castelli, F, Conti, A, Costanzo, A, Cuccia, A, Dapavo, P, Dattola, A, De Simone, C, Di Lernia, V, Dini, V, Donini, M, Errichetti, E, Esposito, M, Fargnoli, M, Foti, A, Fiorella, C, Gargiulo, L, Gisondi, P, Guarneri, C, Legori, A, Lembo, S, Loconsole, F, Malagoli, P, Marzano, A, Mercuri, S, Megna, M, Micali, G, Mortato, E, Musumeci, M, Narcisi, A, Offidani, A, Orsini, D, Paolino, G, Pellacani, G, Peris, K, Potenza, C, Prignano, F, Quaglino, P, Ribero, S, Richetta, A, Romanelli, M, Rossi, A, Strippoli, D, Trovato, E, Venturini, M, Bianchi, L, Campione, Elena, Artosi, Fabio, Shumak, Ruslana Gaeta, Giunta, Alessandro, Argenziano, Giuseppe, Assorgi, Chiara, Balato, Anna, Bernardini, Nicoletta, Brunasso, Alexandra Maria Giovanna, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Carugno, Andrea, Castelli, Franco, Conti, Andrea, Costanzo, Antonio, Cuccia, Aldo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Donini, Massimo, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Foti, Antonio, Fiorella, Carmen, Gargiulo, Luigi, Gisondi, Paolo, Guarneri, Claudio, Legori, Agostina, Lembo, Serena, Loconsole, Francesco, Malagoli, Piergiorigio, Marzano, Angelo Valerio, Mercuri, Santo Raffaele, Megna, Matteo, Micali, Giuseppe, Mortato, Edoardo, Musumeci, Maria Letizia, Narcisi, Alessandra, Offidani, Anna Maria, Orsini, Diego, Paolino, Giovanni, Pellacani, Giovanni, Peris, Ketty, Potenza, Concetta, Prignano, Francesca, Quaglino, Pietro, Ribero, Simone, Richetta, Antonio Giovanni, Romanelli, Marco, Rossi, Antonio, Strippoli, Davide, Trovato, Emanuele, Venturini, Marina, Bianchi, Luca, Campione, E, Artosi, F, Shumak, R, Giunta, A, Argenziano, G, Assorgi, C, Balato, A, Bernardini, N, Brunasso, A, Burlando, M, Caldarola, G, Campanati, A, Carugno, A, Castelli, F, Conti, A, Costanzo, A, Cuccia, A, Dapavo, P, Dattola, A, De Simone, C, Di Lernia, V, Dini, V, Donini, M, Errichetti, E, Esposito, M, Fargnoli, M, Foti, A, Fiorella, C, Gargiulo, L, Gisondi, P, Guarneri, C, Legori, A, Lembo, S, Loconsole, F, Malagoli, P, Marzano, A, Mercuri, S, Megna, M, Micali, G, Mortato, E, Musumeci, M, Narcisi, A, Offidani, A, Orsini, D, Paolino, G, Pellacani, G, Peris, K, Potenza, C, Prignano, F, Quaglino, P, Ribero, S, Richetta, A, Romanelli, M, Rossi, A, Strippoli, D, Trovato, E, Venturini, M, Bianchi, L, Campione, Elena, Artosi, Fabio, Shumak, Ruslana Gaeta, Giunta, Alessandro, Argenziano, Giuseppe, Assorgi, Chiara, Balato, Anna, Bernardini, Nicoletta, Brunasso, Alexandra Maria Giovanna, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Carugno, Andrea, Castelli, Franco, Conti, Andrea, Costanzo, Antonio, Cuccia, Aldo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Donini, Massimo, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Foti, Antonio, Fiorella, Carmen, Gargiulo, Luigi, Gisondi, Paolo, Guarneri, Claudio, Legori, Agostina, Lembo, Serena, Loconsole, Francesco, Malagoli, Piergiorigio, Marzano, Angelo Valerio, Mercuri, Santo Raffaele, Megna, Matteo, Micali, Giuseppe, Mortato, Edoardo, Musumeci, Maria Letizia, Narcisi, Alessandra, Offidani, Anna Maria, Orsini, Diego, Paolino, Giovanni, Pellacani, Giovanni, Peris, Ketty, Potenza, Concetta, Prignano, Francesca, Quaglino, Pietro, Ribero, Simone, Richetta, Antonio Giovanni, Romanelli, Marco, Rossi, Antonio, Strippoli, Davide, Trovato, Emanuele, Venturini, Marina, and Bianchi, Luca

Abstract

(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients’ quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis. Our real-world-evidence multicenter study aims to evaluate the efficacy of bimekizumab in nail psoriasis. (2) Methods: A retrospective analysis of a multicenter observational study included 834 patients affected by moderate-to-severe psoriasis, in 33 Dermatologic Units in Italy, treated with bimekizumab from December 2022 to September 2023. Clinimetric assessments were based on Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) for the severity of nail psoriasis at 0, 12, 24, and 36 weeks. (3) Results: Psoriatic nail involvement was present in 27.95% of patients. The percentage of patients who achieved a complete clearance of NP in terms of PGA-F 0 was 31.7%, 57%, and 88.5% at week 4, 16, and 36, respectively. PASI 100 was achieved by 32.03% of patients at week 4, by 61.8% at week 16, and by 78.92% of patients at week 36. The mean baseline PASI was 16.24. The mean DLQI values for the entire group of patients at baseline, at week 4, at week 16, and at week 36 were 14.62, 3.02, 0.83, and 0.5, respectively. (4) Conclusions: Therapies that promote the healing of both the skin and nails in a short time can also ensure a lower risk of subsequently developing arthritis which is disabling over time. Bimekizumab proved to be particularly effective to treat NP, with a fast response in terms of complete clearance, with over 88.5% of patients free from NP after 36 weeks. The findings of our real-world study showed that patients with moderate-to-severe PsO and concomitant NP had significantly faste

Published
2024

20. The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

Author

Megna, M, Orsini, D, Assorgi, C, Balato, A, Balestri, R, Bianchi, L, Brianti, P, Brunasso, G, Buononato, D, Burlando, M, Cagni, A, Caldarola, G, Cameli, N, Campanati, A, Campione, E, Carrera, C, Carugno, A, Chersi, K, Costanzo, A, Cusano, F, D'Amico, D, Dal Bello, G, Dapavo, P, Dattola, A, De Simone, C, Di Lernia, V, Dini, V, Errichetti, E, Esposito, M, Fargnoli, M, Fiorella, C, Foti, A, Gaiani, F, Gargiulo, L, Gatti, A, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Malagoli, P, Marzano, A, Maurelli, M, Mercuri, S, Michelerio, A, Michelucci, A, Morrone, P, Mortato, E, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Quaglino, P, Richetta, A, Romano, F, Sena, P, Trevisan, G, Uzzauto, M, Venturini, M, Potestio, L, Megna, Matteo, Orsini, Diego, Assorgi, Chiara, Balato, Anna, Balestri, Riccardo, Bianchi, Luca, Brianti, Pina, Brunasso, Giovanna, Buononato, Dario, Burlando, Martina, Cagni, Anna Elisabetta, Caldarola, Giacomo, Cameli, Norma, Campanati, Anna, Campione, Elena, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Costanzo, Antonio, Cusano, Francesco, D'Amico, Domenico, Dal Bello, Giacomo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Fiorella, Carmen Silvia, Foti, Antonio, Gaiani, Francesca Maria, Gargiulo, Luigi, Gatti, Alessandro, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Malagoli, Piergiorgio, Marzano, Angelo Valerio, Maurelli, Martina, Mercuri, Santo Raffaele, Michelerio, Andrea, Michelucci, Alessandra, Morrone, Pietro, Mortato, Edoardo, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Quaglino, Pietro, Richetta, Antonio Giovanni, Romano, Francesca, Sena, Paolo, Trevisan, Giampaolo, Uzzauto, Maria Teresa, Venturini, Marina, Potestio, Luca, Megna, M, Orsini, D, Assorgi, C, Balato, A, Balestri, R, Bianchi, L, Brianti, P, Brunasso, G, Buononato, D, Burlando, M, Cagni, A, Caldarola, G, Cameli, N, Campanati, A, Campione, E, Carrera, C, Carugno, A, Chersi, K, Costanzo, A, Cusano, F, D'Amico, D, Dal Bello, G, Dapavo, P, Dattola, A, De Simone, C, Di Lernia, V, Dini, V, Errichetti, E, Esposito, M, Fargnoli, M, Fiorella, C, Foti, A, Gaiani, F, Gargiulo, L, Gatti, A, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Malagoli, P, Marzano, A, Maurelli, M, Mercuri, S, Michelerio, A, Michelucci, A, Morrone, P, Mortato, E, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Quaglino, P, Richetta, A, Romano, F, Sena, P, Trevisan, G, Uzzauto, M, Venturini, M, Potestio, L, Megna, Matteo, Orsini, Diego, Assorgi, Chiara, Balato, Anna, Balestri, Riccardo, Bianchi, Luca, Brianti, Pina, Brunasso, Giovanna, Buononato, Dario, Burlando, Martina, Cagni, Anna Elisabetta, Caldarola, Giacomo, Cameli, Norma, Campanati, Anna, Campione, Elena, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Costanzo, Antonio, Cusano, Francesco, D'Amico, Domenico, Dal Bello, Giacomo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Fiorella, Carmen Silvia, Foti, Antonio, Gaiani, Francesca Maria, Gargiulo, Luigi, Gatti, Alessandro, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Malagoli, Piergiorgio, Marzano, Angelo Valerio, Maurelli, Martina, Mercuri, Santo Raffaele, Michelerio, Andrea, Michelucci, Alessandra, Morrone, Pietro, Mortato, Edoardo, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Quaglino, Pietro, Richetta, Antonio Giovanni, Romano, Francesca, Sena, Paolo, Trevisan, Giampaolo, Uzzauto, Maria Teresa, Venturini, Marina, and Potestio, Luca

Published
2024

21. The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

Author

Megna, Matteo, Orsini, Diego, Assorgi, Chiara, Balato, Anna, Balestri, Riccardo, Bianchi, Luca, Brianti, Pina, Brunasso, Giovanna, Buononato, Dario, Burlando, Martina, Cagni, Anna Elisabetta, Caldarola, Giacomo, Cameli, Norma, Campanati, Anna, Campione, Elena, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Costanzo, Antonio, Cusano, Francesco, D'Amico, Domenico, Dal Bello, Giacomo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Fiorella, Carmen Silvia, Foti, Antonio, Gaiani, Francesca Maria, Gargiulo, Luigi, Gatti, Alessandro, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Malagoli, Piergiorgio, Marzano, Angelo Valerio, Maurelli, Martina, Mercuri, Santo Raffaele, Michelerio, Andrea, Michelucci, Alessandra, Morrone, Pietro, Mortato, Edoardo, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Quaglino, Pietro, Richetta, Antonio Giovanni, Romano, Francesca, Sena, Paolo, Trevisan, Giampaolo, Uzzauto, Maria Teresa, Venturini, Marina, Potestio, Luca, Caldarola, Giacomo (ORCID:0000-0002-8837-9232), De Simone, Clara (ORCID:0000-0002-0898-0045), Megna, Matteo, Orsini, Diego, Assorgi, Chiara, Balato, Anna, Balestri, Riccardo, Bianchi, Luca, Brianti, Pina, Brunasso, Giovanna, Buononato, Dario, Burlando, Martina, Cagni, Anna Elisabetta, Caldarola, Giacomo, Cameli, Norma, Campanati, Anna, Campione, Elena, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Costanzo, Antonio, Cusano, Francesco, D'Amico, Domenico, Dal Bello, Giacomo, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Di Lernia, Vito, Dini, Valentina, Errichetti, Enzo, Esposito, Maria, Fargnoli, Maria Concetta, Fiorella, Carmen Silvia, Foti, Antonio, Gaiani, Francesca Maria, Gargiulo, Luigi, Gatti, Alessandro, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Malagoli, Piergiorgio, Marzano, Angelo Valerio, Maurelli, Martina, Mercuri, Santo Raffaele, Michelerio, Andrea, Michelucci, Alessandra, Morrone, Pietro, Mortato, Edoardo, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Quaglino, Pietro, Richetta, Antonio Giovanni, Romano, Francesca, Sena, Paolo, Trevisan, Giampaolo, Uzzauto, Maria Teresa, Venturini, Marina, Potestio, Luca, Caldarola, Giacomo (ORCID:0000-0002-8837-9232), and De Simone, Clara (ORCID:0000-0002-0898-0045)

Abstract

n/A

Published
2024

22. Gender influence and bimekizumab treatment in moderate-to-severe psoriasis: a short term real-life multicenter experience

Author

Diotallevi, F, Richiardi, I, Shevchuk, A, Esposito, M, Vagnozzi, E, Concetta Fargnoli, M, Gisondi, P, Bellinato, F, Assorgi, C, Orsini, D, Brianti, P, Raffaele Mercuri, S, Burlando, M, Cozzani, E, Brunasso, G, Caccavale, S, Di Caprio, R, Balato, A, Caldarola, G, De Simone, C, Campione, E, Giunta, A, Calzavara Pinton, P, Venturini, M, Giovanni Carrera, C, Valerio Marzano, A, Carugno, A, Sena, P, Costanzo, A, Narcisi, A, Cusano, F, Dapavo, P, Quaglino, P, Dattola, A, Giovanni Richetta, A, Gaiani, F, Malagoli, P, Megna, M, Potestio, L, Mortato, E, Loconsole, F, Romano, F, Faragalli, A, Gesuita, R, Campanati, A, Diotallevi, Federico, Richiardi, Irene, Shevchuk, Anna, Esposito, Maria, Vagnozzi, Emanuele, Concetta Fargnoli, Maria, Gisondi, Paolo, Bellinato, Francesco, Assorgi, Chiara, Orsini, Diego, Brianti, Pina, Raffaele Mercuri, Santo, Burlando, Martina, Cozzani, Emanuele, Brunasso, Giovanna, Caccavale, Stefano, Di Caprio, Roberta, Balato, Anna, Caldarola, Giacomo, De Simone, Clara, Campione, Elena, Giunta, Alessandro, Calzavara Pinton, Piergiorgio, Venturini, Marina, Giovanni Carrera, Carlo, Valerio Marzano, Angelo, Carugno, Andrea, Sena, Paolo, Costanzo, Antonio, Narcisi, Alessandra, Cusano, Francesco, Dapavo, Paolo, Quaglino, Pietro, Dattola, Annunziata, Giovanni Richetta, Antonio, Gaiani, Francesca, Malagoli, Piergiorgio, Megna, Matteo, Potestio, Luca, Mortato, Edoardo, Loconsole, Francesco, Romano, Francesca, Faragalli, Andrea, Gesuita, Rosaria, Campanati, Anna, Diotallevi, F, Richiardi, I, Shevchuk, A, Esposito, M, Vagnozzi, E, Concetta Fargnoli, M, Gisondi, P, Bellinato, F, Assorgi, C, Orsini, D, Brianti, P, Raffaele Mercuri, S, Burlando, M, Cozzani, E, Brunasso, G, Caccavale, S, Di Caprio, R, Balato, A, Caldarola, G, De Simone, C, Campione, E, Giunta, A, Calzavara Pinton, P, Venturini, M, Giovanni Carrera, C, Valerio Marzano, A, Carugno, A, Sena, P, Costanzo, A, Narcisi, A, Cusano, F, Dapavo, P, Quaglino, P, Dattola, A, Giovanni Richetta, A, Gaiani, F, Malagoli, P, Megna, M, Potestio, L, Mortato, E, Loconsole, F, Romano, F, Faragalli, A, Gesuita, R, Campanati, A, Diotallevi, Federico, Richiardi, Irene, Shevchuk, Anna, Esposito, Maria, Vagnozzi, Emanuele, Concetta Fargnoli, Maria, Gisondi, Paolo, Bellinato, Francesco, Assorgi, Chiara, Orsini, Diego, Brianti, Pina, Raffaele Mercuri, Santo, Burlando, Martina, Cozzani, Emanuele, Brunasso, Giovanna, Caccavale, Stefano, Di Caprio, Roberta, Balato, Anna, Caldarola, Giacomo, De Simone, Clara, Campione, Elena, Giunta, Alessandro, Calzavara Pinton, Piergiorgio, Venturini, Marina, Giovanni Carrera, Carlo, Valerio Marzano, Angelo, Carugno, Andrea, Sena, Paolo, Costanzo, Antonio, Narcisi, Alessandra, Cusano, Francesco, Dapavo, Paolo, Quaglino, Pietro, Dattola, Annunziata, Giovanni Richetta, Antonio, Gaiani, Francesca, Malagoli, Piergiorgio, Megna, Matteo, Potestio, Luca, Mortato, Edoardo, Loconsole, Francesco, Romano, Francesca, Faragalli, Andrea, Gesuita, Rosaria, and Campanati, Anna

Published
2024

23. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

Author

Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, Costanzo, Antonio, Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, and Costanzo, Antonio

Abstract

Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician's Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index. Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. Moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index (DLQI), signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.

Published
2024

24. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra, Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, and Narcisi, Alessandra

Abstract

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.

Published
2024

28. Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers–Danlos Syndrome: Focus on Vascular Prevention.

Author

Buso, Giacomo, Corvini, Federica, Fusco, Elena Maria, Messina, Massimiliano, Cherubini, Fabio, Laera, Nicola, Paini, Anna, Salvetti, Massimo, De Ciuceis, Carolina, Ritelli, Marco, Venturini, Marina, Chiarelli, Nicola, Colombi, Marina, and Muiesan, Maria Lorenza

Subjects
CONNECTIVE tissue diseases, DRUG therapy, NON-coding RNA, THERAPEUTICS, SURVIVAL rate, EHLERS-Danlos syndrome
Abstract

Vascular Ehlers–Danlos syndrome (vEDS) is a rare autosomal dominant connective tissue disease resulting from pathogenic variants in the collagen type III alpha 1 chain (COL3A1) gene, encoding type III procollagen. Patients with vEDS present with severe tissue fragility that can result in arterial aneurysm, dissection, or rupture, especially of medium-caliber vessels. Although early reports have indicated a very high mortality rate in affected patients, with an estimated median survival of around 50 years, recent times have seen a remarkable improvement in outcomes in this population. This shift could be related to greater awareness of the disease among patients and physicians, with improved management both in terms of follow-up and treatment of complications. Increasing use of drugs acting on the cardiovascular system may also have contributed to this improvement. In particular, celiprolol, a β1 cardio-selective blocker with a β2-agonist vasodilator effect, has been shown to reduce rates of vascular events in patients with vEDS. However, the evidence on the true benefits and possible mechanisms responsible for the protective effect of celiprolol in this specific setting remains limited. Drugs targeting the extracellular matrix organization and autophagy–lysosome pathways are currently under investigation and could play a role in the future. This narrative review aims to summarize current evidence and future perspectives on vEDS medical treatment, with a specific focus on vascular prevention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis

Author

Prignano, Francesca, primary, Argenziano, Giuseppe, additional, Bardazzi, Federico, additional, Borroni, Riccardo G., additional, Brunasso, Alexandra M. G., additional, Burlando, Martina, additional, Cagni, Anna Elisabetta, additional, Campione, Elena, additional, Cinotti, Elisa, additional, Colonna, Fabrizio, additional, Cuccia, Aldo, additional, Dastoli, Stefano, additional, De Pasquale, Rocco, additional, De Simone, Clara, additional, Di Lernia, Vito, additional, Dini, Valentina, additional, Fabbrocini, Gabriella, additional, Galluzzi, Claudia, additional, Giacchetti, Alfredo, additional, Giofrè, Claudia, additional, Lasagni, Claudia, additional, Lembo, Serena, additional, Loconsole, Francesco, additional, Montesu, Maria Antonia, additional, Pella, Paolo, additional, Piaserico, Stefano, additional, Pigatto, Paolo, additional, Richetta, Antonio Giovanni, additional, Scuotto, Adriana, additional, Stroppiana, Elena, additional, Venturini, Marina, additional, Vinci, Anna Stefania, additional, Zichichi, Leonardo, additional, and Fargnoli, Maria Concetta, additional

Published
2023
Full Text
View/download PDF

31. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo, Filomena, primary, Galluzzo, Marco, additional, Stingeni, Luca, additional, Persechino, Severino, additional, Zichichi, Leonardo, additional, Conti, Andrea, additional, Giofrè, Claudia, additional, Dini, Valentina, additional, Vispi, Martina, additional, Atzori, Laura, additional, Cattaneo, Angelo, additional, Parodi, Aurora, additional, Bardazzi, Federico, additional, Stinco, Giuseppe, additional, Dapavo, Paolo, additional, Girolomoni, Giampiero, additional, Musumeci, Maria Letizia, additional, Papini, Manuela, additional, Venturini, Marina, additional, Dastoli, Stefano, additional, Di Nuzzo, Sergio, additional, Fargnoli, Maria Concetta, additional, Pagnanelli, Gianluca, additional, Bernardini, Nicoletta, additional, Gambini, Daniele, additional, Malagoli, Piergiorgio, additional, Mazzatenta, Carlo, additional, Peris, Ketty, additional, Zalaudek, Iris, additional, Fabbrocini, Gabriella, additional, Loconsole, Francesco, additional, Vassallo, Camilla, additional, Pietroleonardo, Lucia, additional, Prignano, Francesca, additional, Franchi, Chiara, additional, Offidani, Anna Maria, additional, Bonifati, Claudio, additional, Di Lernia, Vito, additional, Gigante, Giovanni, additional, Bartezaghi, Marta, additional, Franchi, Matteo, additional, Ursoleo, Paola, additional, and Aloisi, Elisabetta, additional

Published
2023
Full Text
View/download PDF

35. Despite celiprolol therapy, patients with vascular Ehlers–Danlos syndrome remain at risk of vascular events: A 12-year experience in an Italian referral center.

Author

Buso, Giacomo, Paini, Anna, Agabiti-Rosei, Claudia, De Ciuceis, Carolina, Bertacchini, Fabio, Stassaldi, Deborah, Salvetti, Massimo, Ritelli, Marco, Venturini, Marina, Colombi, Marina, and Muiesan, Maria Lorenza

Subjects
EHLERS-Danlos syndrome, BLOOD pressure measurement, MEDICAL offices, CONNECTIVE tissues
Abstract

Background: Vascular Ehlers–Danlos syndrome (vEDS) is an inherited connective tissue disorder characterized by arterial fragility. Celiprolol has been suggested to significantly reduce rates of vascular events in this setting, though real-world evidence is limited. The aim of this study was to report our experience with celiprolol therapy in vEDS management. Methods: Patients with a genetically confirmed diagnosis of vEDS who were referred for outpatient consultation at the Brescia University Hospital between January 2011 and July 2023 were included. At each visit, patients' medical history, results of vascular imaging, and office blood pressure measurements were recorded. Celiprolol therapy was progressively titrated to the maximum tolerated dose of up to 400 mg daily, according to the patients' tolerance. Results: Overall, 26 patients were included. Female sex was prevalent (62%). Mean (SD) age was 37 (16) years. Follow-up duration was 72 (41) months. At the last follow-up visit, all patients were on celiprolol therapy, 80% of whom were taking the maximum recommended dose. The yearly risk of symptomatic vascular events was 8.8%, the majority of which occurred after reaching the maximum recommended dose of celiprolol. No significant predictor of symptomatic vascular events was identified among patients' clinical characteristics. Conclusion: In our cohort, rates of celiprolol use were high and the drug was well tolerated overall. Nonetheless, the risk of symptomatic vascular events remained nonnegligible. Future studies should identify reliable predictors of major adverse events and explore additional therapeutic strategies that could further lower the risk of life-threatening events in this population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, Luigi, primary, Narcisi, Alessandra, additional, Ibba, Luciano, additional, Balato, Anna, additional, Bianchi, Luca, additional, Brianti, Pina, additional, Buononato, Dario, additional, Burlando, Martina, additional, Caldarola, Giacomo, additional, Campanati, Anna, additional, Campione, Elena, additional, Carrera, Carlo G., additional, Carugno, Andrea, additional, Cristaudo, Antonio, additional, Cusano, Francesco, additional, Dapavo, Paolo, additional, Dattola, Annunziata, additional, De Simone, Clara, additional, Gaiani, Francesca M., additional, Gisondi, Paolo, additional, Giunta, Alessandro, additional, Loconsole, Francesco, additional, Maione, Vincenzo, additional, Mortato, Edoardo, additional, Marzano, Angelo V., additional, Maurelli, Martina, additional, Megna, Matteo, additional, Mercuri, Santo R., additional, Offidani, Annamaria, additional, Orsini, Diego, additional, Parodi, Aurora, additional, Pellacani, Giovanni, additional, Potestio, Luca, additional, Quaglino, Pietro, additional, Richetta, Antonio G., additional, Romano, Francesca, additional, Sena, Paolo, additional, Venturini, Marina, additional, Malagoli, Piergiorgio, additional, and Costanzo, Antonio, additional

Published
2023
Full Text
View/download PDF

39. Hidradenitis suppurativa and adalimumab in the COVID-19 era

Author

Marzano, Angelo Valerio, Moltrasio, Chiara, Genovese, Giovanni, Muratori, Simona, Dapavo, Paolo, Fabbrocini, Gabriella, Patrizi, Annalisa, Sechi, Andrea, Micali, Giuseppe, Pellegrino, Michele, Gisondi, Paolo, Dini, Valentina, Bianchi, Luca, Fania, Luca, Offidani, Annamaria, Prignano, Francesca, Atzori, Laura, Miraglia, Emanuele, Cannavò, Serafinella Patrizia, Bettoli, Vincenzo, Stingeni, Luca, Balestri, Riccardo, Venturini, Marina, and Peris, Ketty

Published
2020
Full Text
View/download PDF

40. List of Contributors

Author

Afek, Arnon, primary, Afeltra, Antonella, additional, Afflitto, Gabriele Gallo, additional, Alessandri, Cristiano, additional, Alivernini, Stefano, additional, Alunno, Alessia, additional, Amital, Howard, additional, Andreoli, Laura, additional, Antonelli, Alessandro, additional, Arisi, Mariachiara, additional, Artusi, Carolina, additional, Atzeni, Fabiola, additional, Ballanti, Eleonora, additional, Barbati, Cristiana, additional, Barilaro, Giuseppe, additional, Bartoloni, Elena, additional, Ben-Ami, Dana, additional, Bettencourt, Andreia, additional, Bizzaro, Nicola, additional, Blank, Miri, additional, Bogdanos, Dimitrios P., additional, Boleixa, Daniela, additional, Borba, Vânia Vieira, additional, Borgiani, Paola, additional, Bragazzi, Nicola Luigi, additional, Brzosko, Iwona, additional, Brzosko, Marek, additional, Calzavara-Pinton, Piergiacomo, additional, Campi, Irene, additional, Cantarini, Luca, additional, Carranza-Muleiro, Rosa A., additional, Carvalho, Cláudia, additional, Caso, Francesco, additional, Ceccarelli, Fulvia, additional, Cervera, Ricard, additional, Chapman, Joab, additional, Chen, Xian, additional, Chimenti, Maria Sole, additional, Ciccacci, Cinzia, additional, Cipriano, Enrica, additional, Cohen Tervaert, Jan Willem, additional, Colasanti, Tania, additional, Conigliaro, Paola, additional, Conti, Fabrizio, additional, Coplan, Louis, additional, Costa, Luisa, additional, Croci, Stefania, additional, Cruz-Domínguez, María del Pilar, additional, Cutolo, Maurizio, additional, Dahan, Shani, additional, Damoiseaux, Jan, additional, De Carolis, Caterina, additional, Del Puente, Antonio, additional, Domingues, Vinicius, additional, Dreyfus, David H., additional, Drori, Tali, additional, Ehrenfeld, Michael, additional, Espinosa, Gerard, additional, Farina, Antonella, additional, Farina, Giuseppina Alessandra, additional, Ferraccioli, Gianfranco, additional, Finucci, Annacarla, additional, Fioravanti, Antonella, additional, Fischer, Katarzyna, additional, Fonti, Giulia Lavinia, additional, Francesca, Barone, additional, Franceschini, Franco, additional, Freire de Carvalho, Jozélio, additional, Fujio, Keishi, additional, García-Collinot, Grettel, additional, Generali, Elena, additional, Gerardi, Maria Chiara, additional, Gerli, Roberto, additional, Gertel, Smadar, additional, Giat, Eitan, additional, Greco, Elisabetta, additional, Gremese, Elisa, additional, Grunebaum, Eyal, additional, Gualtierotti, Roberta, additional, Guarino, Maria Domenica, additional, Guzner-Gur, Hanan, additional, He, Shu-Gui, additional, Iannuccelli, Cristina, additional, Jara, Luis J., additional, Jeandel, Pierre-Yves, additional, Kivity, Dr Shaye, additional, Kotyla, Przemyslaw J., additional, Krosser, Alec, additional, Latini, Andrea, additional, Leon-Ponte, Matilde, additional, Lerner, Aaron, additional, Levy, Roger Abramino, additional, Lichtbroun, Benjamin, additional, Lucchetti, Ramona, additional, Lu, Qianjin, additional, Margiotta, Domenico P.E., additional, Marinho, António, additional, Martínez-Bencomo, Michel A., additional, Matthias, Torsten, additional, Medina, Gabriela, additional, Meroni, Pier Luigi, additional, Lichtbroun, Michael, additional, Moreira Balbi, Gustavo Guimarães, additional, Muratore, Francesco, additional, Navarini, Luca, additional, Novelli, Giuseppe, additional, Pacucci, Viviana Antonella, additional, Peluso, Rosario, additional, Pendolino, Monica, additional, Pérez, Dolores, additional, Perricone, Carlo, additional, Perricone, Roberto, additional, Persani, Luca, additional, Petricca, Luca, additional, Pipitone, Nicolò, additional, Ramires de Jesús, Guilherme, additional, Resende, Gustavo, additional, Rizenbah, Chen, additional, Rodríguez-Pintó, Ignasi, additional, Rose, Noel R., additional, Rosenthal, Eric, additional, Rossi, Mariateresa, additional, Sakkas, Lazaros I., additional, Salvarani, Carlo, additional, Sarzi-Puttini, Piercarlo, additional, Scarpa, Raffaele, additional, Segal, Yahel, additional, Segel, Michael J., additional, Selmi, Carlo, additional, Seluk, Dr Lior, additional, Serena, Colafrancesco, additional, Sharabi, Amir, additional, Sharif, Kassem, additional, Shoenfeld, Netta, additional, Shoenfeld, Yehuda, additional, Signorelli, Flavio, additional, Silva, Ana Martins, additional, Silva, Berta Martins, additional, Slomovich, Sharon, additional, Somech, Raz, additional, Soriano, Alessandra, additional, Szekanecz, Zoltán, additional, Tanaka, Yoshiya, additional, Tenti, Sara, additional, Tincani, Angela, additional, Tolusso, Barbara, additional, Torres-Ruiz, Jiram, additional, Toubi, Elias, additional, Tozzoli, Renato, additional, Triggianese, Paola, additional, Trombetta, Amelia Chiara, additional, Tsokos, George C., additional, Tsuchida, Yumi, additional, Vadasz, Zahava, additional, Valesini, Guido, additional, van Beers, Joyce, additional, van Paassen, Pieter, additional, Vannucchi, Guia Maria, additional, Vasconcelos, Carlos, additional, Venturini, Marina, additional, Vera-Lastra, Olga, additional, Versini, Mathilde, additional, Vomero, Marta, additional, Watad, Abdulla, additional, Wu, Haijing, additional, and Zeng, Yong, additional

Published
2019
Full Text
View/download PDF

41. Ultraviolet Radiation

Author

Venturini, Marina, primary, Andreoli, Laura, additional, Arisi, Mariachiara, additional, Rossi, Mariateresa, additional, Franceschini, Franco, additional, Calzavara-Pinton, Piergiacomo, additional, and Tincani, Angela, additional

Published
2019
Full Text
View/download PDF

42. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo,Filomena, Galluzzo,Marco, Stingeni,Luca, Persechino,Severino, Zichichi,Leonardo, Conti,Andrea, Giofrè,Claudia, Dini,Valentina, Vispi,Martina, Atzori,Laura, Cattaneo,Angelo, Parodi,Aurora, Bardazzi,Federico, Stinco,Giuseppe, Dapavo,Paolo, Girolomoni,Giampiero, Musumeci,Maria Letizia, Papini,Manuela, Venturini,Marina, Dastoli,Stefano, Di Nuzzo,Sergio, Fargnoli,Maria Concetta, Pagnanelli,Gianluca, Bernardini,Nicoletta, Gambini,Daniele, Malagoli,Piergiorgio, Mazzatenta,Carlo, Peris,Ketty, Zalaudek,Iris, Fabbrocini,Gabriella, Loconsole,Francesco, Vassallo,Camilla, Pietroleonardo,Lucia, Prignano,Francesca, Franchi,Chiara, Offidani,Anna Maria, Bonifati,Claudio, Di Lernia,Vito, Gigante,Giovanni, Bartezaghi,Marta, Franchi,Matteo, Ursoleo,Paola, Aloisi,Elisabetta, Russo,Filomena, Galluzzo,Marco, Stingeni,Luca, Persechino,Severino, Zichichi,Leonardo, Conti,Andrea, Giofrè,Claudia, Dini,Valentina, Vispi,Martina, Atzori,Laura, Cattaneo,Angelo, Parodi,Aurora, Bardazzi,Federico, Stinco,Giuseppe, Dapavo,Paolo, Girolomoni,Giampiero, Musumeci,Maria Letizia, Papini,Manuela, Venturini,Marina, Dastoli,Stefano, Di Nuzzo,Sergio, Fargnoli,Maria Concetta, Pagnanelli,Gianluca, Bernardini,Nicoletta, Gambini,Daniele, Malagoli,Piergiorgio, Mazzatenta,Carlo, Peris,Ketty, Zalaudek,Iris, Fabbrocini,Gabriella, Loconsole,Francesco, Vassallo,Camilla, Pietroleonardo,Lucia, Prignano,Francesca, Franchi,Chiara, Offidani,Anna Maria, Bonifati,Claudio, Di Lernia,Vito, Gigante,Giovanni, Bartezaghi,Marta, Franchi,Matteo, Ursoleo,Paola, and Aloisi,Elisabetta

Abstract

Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,15 Paolo Dapavo,16 Giampiero Girolomoni,17 Maria Letizia Musumeci,18 Manuela Papini,19 Marina Venturini,20 Stefano Dastoli,21 Sergio Di Nuzzo,22 Maria Concetta Fargnoli,23 Gianluca Pagnanelli,24 Nicoletta Bernardini,25 Daniele Mario Gambini,26 Piergiorgio Malagoli,27 Carlo Mazzatenta,28 Ketty Peris,29 Iris Zalaudek,30 Gabriella Fabbrocini31 ,†Francesco Loconsole,32 Camilla Vassallo,33 Lucia Pietroleonardo,34 Francesca Prignano,35 Chiara Franchi,36 Anna Maria Offidani,37 Claudio Bonifati,38 Vito Di Lernia,39 Giovanni Gigante,40 Marta Silvia Bartezaghi,40 Matteo Franchi,41,42 Paola Ursoleo,40 Elisabetta Aloisi40 1Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy; 2Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy; 4Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Dermatology Unit, NESMOS Department, Faculty of Medicine & Psychology, Sapienza University of Rome, Sant’Andrea University Hospital, Rome, Italy; 6Unit of Dermatology, San Antonio Abate Hospital, Trapani, Italy; 7Section of Dermatology, Department of Specialized Medicine, University of Modena and Reggio Emilia, Modena, Italy; 8U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 9Section of Dermatology, Department of Medicine and Oncology, University of Pisa, Pisa, Italy; 10Dermatology Unit, Misericordia Hospital, Grosseto, Italy; 11Dermatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 12Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policl

Published
2023

43. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, Costanzo, Antonio, Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, and Costanzo, Antonio

Abstract

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

Published
2023

44. Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study

Author

Bellinato, F, Gisondi, P, Marzano, A, Piaserico, S, De Simone, C, Damiani, G, Argenziano, G, Venturini, M, Dapavo, P, Costanzo, A, Megna, M, Prignano, F, Burlando, M, Satolli, F, Carugno, A, Pezzolo, E, Romanelli, M, Cuccia, A, Girolomoni, G, Bellinato, Francesco, Gisondi, Paolo, Marzano, Angelo Valerio, Piaserico, Stefano, De Simone, Clara, Damiani, Giovanni, Argenziano, Giuseppe, Venturini, Marina, Dapavo, Paolo, Costanzo, Antonio, Megna, Matteo, Prignano, Francesca, Burlando, Martina, Satolli, Francesca, Carugno, Andrea, Pezzolo, Elena, Romanelli, Marco, Cuccia, Aldo, Girolomoni, Giampiero, Bellinato, F, Gisondi, P, Marzano, A, Piaserico, S, De Simone, C, Damiani, G, Argenziano, G, Venturini, M, Dapavo, P, Costanzo, A, Megna, M, Prignano, F, Burlando, M, Satolli, F, Carugno, A, Pezzolo, E, Romanelli, M, Cuccia, A, Girolomoni, G, Bellinato, Francesco, Gisondi, Paolo, Marzano, Angelo Valerio, Piaserico, Stefano, De Simone, Clara, Damiani, Giovanni, Argenziano, Giuseppe, Venturini, Marina, Dapavo, Paolo, Costanzo, Antonio, Megna, Matteo, Prignano, Francesca, Burlando, Martina, Satolli, Francesca, Carugno, Andrea, Pezzolo, Elena, Romanelli, Marco, Cuccia, Aldo, and Girolomoni, Giampiero

Abstract

Background: Generalized pustular psoriasis (GPP) is a rare, severe inflammatory skin disease characterized by recurrent episodes of flares. Characteristics of patients experiencing a flare are hardly described in a real-life setting. The aim of the study is to investigate the clinical characteristics of patients experiencing a flare of GPP. Methods: Multicenter retrospective observational study on consecutive patients experiencing a flare of GPP between 2018 and 2022. Disease severity and quality of life were assessed by Generalized Pustular Psoriasis Area, Body Surface Area (BSA), and Severity Index (GPPASI), and Dermatology life quality index (DLQI) questionnaire, respectively. Visual analogue scale (VAS) of itch and pain, triggers, complications, comorbidities, pharmacological therapies, and outcome were collected. Results: A total of 66 patients, 45 (68.2%) females, mean age 58.1 ± 14.9 years, were included. The GPPASI, BSA, and DLQI were 22.9 ± 13.5 (mean ± standard deviation), 47.9 ± 29.1, and 21.0 ± 5.0, respectively. The VAS of itch and pain were 6.2 ± 3.3 and 6.2 ± 3.0, respectively. Fever (>38 °C) and leukocytosis (WBC > 12 × 109/L) were found in 26 (39.4%) and 39 (59.1%) patients, respectively. Precipitating triggers were identified in 24 (36.3%) and included infections (15.9%), drugs (10.6%), stressful life events (7.6%), and corticosteroids withdrawal (3.0%). Fourteen (21.2%) patients were hospitalized because of complications including infections in 9 (13.6%) leading to death in one case and hepatitis in 3 (4.5%). Conclusions: GPP flares can be severe and cause severe pain and itch with significant impact on the quality of life. In about one-third of patients the flare may have a persistent course and, with complications, lead to hospitalization.

Published
2023

45. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, Aloisi, Elisabetta, Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, and Aloisi, Elisabetta

Abstract

Purpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks. Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts. Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings. Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.

Published
2023

46. Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers‐Danlos syndrome: A retrospective cross‐sectional study from an Italian reference center.

Author

Ritelli, Marco, Chiarelli, Nicola, Cinquina, Valeria, Vezzoli, Marika, Venturini, Marina, and Colombi, Marina

Abstract

The most common conditions with symptomatic joint hypermobility are hypermobile Ehlers‐Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). Diagnosing these overlapping connective tissue disorders remains challenging due to the lack of established causes and reliable diagnostic tests. hEDS is diagnosed applying the 2017 diagnostic criteria, and patients with symptomatic joint hypermobility but not fulfilling these criteria are labeled as HSD, which is not officially recognized by all healthcare systems. The 2017 criteria were introduced to improve diagnostic specificity but have faced criticism for being too stringent and failing to adequately capture the multisystemic involvement of hEDS. Herein, we retrospectively evaluated 327 patients from 213 families with a prior diagnosis of hypermobility type EDS or joint hypermobility syndrome based on Villefranche and Brighton criteria, to assess the effectiveness of the 2017 criteria in distinguishing between hEDS and HSD and document the frequencies of extra‐articular manifestations. Based on our findings, we propose that the 2017 criteria should be made less stringent to include a greater number of patients who are currently encompassed within the HSD category. This will lead to improved diagnostic accuracy and enhanced patient care by properly capturing the diverse range of symptoms and manifestations present within the hEDS/HSD spectrum. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

Author

Fargnoli, Maria Concetta, primary, Bardazzi, Federico, additional, Bianchi, Luca, additional, Dapavo, Paolo, additional, Fabbrocini, Gabriella, additional, Gisondi, Paolo, additional, Micali, Giuseppe, additional, Offidani, Anna Maria, additional, Pellacani, Giovanni, additional, Skroza, Nevena, additional, Angileri, Rosa Giuseppa, additional, Burlando, Martina, additional, Campanati, Anna, additional, Carrera, Carlo Giovanni, additional, Chiricozzi, Andrea, additional, Conti, Andrea, additional, Simone, Clara De, additional, Di Lernia, Vito, additional, Errichetti, Enzo, additional, Galluzzo, Marco, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Lembo, Serena, additional, Loconsole, Francesco, additional, Megna, Matteo, additional, Musumeci, Maria Letizia, additional, Prignano, Francesca, additional, Richetta, Antonio Giovanni, additional, Trovato, Emanuele, additional, Venturini, Marina, additional, Peris, Ketty, additional, and Pinton, Piergiacomo Calzavara, additional

Published
2023
Full Text
View/download PDF

48. Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics

Author

Rossi, Mariateresa, primary, Damiani, Caterina, additional, Arisi, Mariachiara, additional, Tomasi, Cesare, additional, Tonon, Francesco, additional, Venturini, Marina, additional, and Calzavara-Pinton, Piergiacomo, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results